Bcl-2 Expression and Radiotherapy in Laryngeal Cancer
Author Information
Author(s): Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N
Primary Institution: Postgraduate Medical Institute, University of Hull in association with Hull York Medical School, Hull, UK
Hypothesis
Can Bcl-2 expression predict radiotherapy failure in laryngeal cancer?
Conclusion
Bcl-2 expression is associated with radioresistance in laryngeal cancer, suggesting it could help predict treatment outcomes.
Supporting Evidence
- 53% of radioresistant tumours expressed Bcl-2 compared to 11% in radiosensitive tumours.
- Bcl-XL was expressed by 91% of radioresistant tumours compared to 73% of radiosensitive tumours.
- 43% of radioresistant tumours expressed bax compared to 66% in radiosensitive tumours.
- Bcl-2 has an accuracy of 71% in predicting radiotherapy outcome.
Takeaway
This study found that measuring a protein called Bcl-2 can help doctors know if radiotherapy will work for laryngeal cancer patients.
Methodology
A retrospective analysis comparing 62 radioresistant and 62 radiosensitive laryngeal cancer patients using immunohistochemistry.
Potential Biases
Potential bias in patient selection and retrospective data collection.
Limitations
The study is retrospective and may have confounding factors despite matching groups.
Participant Demographics
Average age of radioresistant group was 64 years, and 62 years for radiosensitive group; included both genders.
Statistical Information
P-Value
p<0.001 for Bcl-2 expression
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website